Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials

We highlight the potential impact of these agents for the future therapeutic landscape of this disease with special emphasis on clinical impact, unmet needs, safety aspects, and advanced combination therapy.